The drug and biotech industry has done well this year, driven by increased mergers and acquisitions (M&A), the launch of ...

Last week, two of the three major U.S. indexes ended in red due to a profit-booking spree by investors. The Nasdaq Composite ...

Chicago, IL – October 7, 2024 – Today, Zacks Investment Ideas feature highlights Taiwan Semiconductor TSM, Netflix NFLX, ...

Zacks Dividend Fund earns a Below Average Process Pillar rating. The process benefits from the experience of the management team, which averages 30 years at this fund. However, the rating is held ...

Zacks All-Cap Core Fund earns an Average Process Pillar rating. The main driver of the rating is the experience of the management team, which averages 30 years at this fund. Excellent risk ...

Despite the challenges, pipeline players are in a stronger position than upstream and downstream firms, as they benefit from ...

The earnings outlook for its current fiscal year remains bullish, with the $1.56 Zacks Consensus EPS estimate up 15% over the last year. Its latest positive results were driven by record royalty ...

Terms may apply to offers listed on this page. Marrying the extensive research of Zacks Investment Research and the low margin rates of Interactive Brokers, Zacks Trade is an incredibly attractive ...

AngioDynamics expects full-year earnings in the range of 38 cents to 42 cents per share, with revenue in the range of $282 million to $288 million. AngioDynamics shares have decreased slightly more ...

The Eagle, Idaho-based company said it had profit of 88 cents per share. Earnings, adjusted for non-recurring gains, were 73 ...